发明名称 Method and kit for establishing an in vitro prognosis on a patient exhibiting SIRS
摘要 A method and a kit for establishing an in vitro prognosis on a patient exhibiting SIRS, the method comprising: (i) measuring the level of expression of the CX3CR1 gene in vitro from the biological material of a patient sample by bringing into contact said sample with a specific reagent of the CX3CR1 gene; and (ii) comparing the expression level of the CX3CR1 gene of the patient to a predetermined expression threshold; wherein (iii) if the expression level of the CX3CR1 gene of the patient is less than the predetermined expression threshold, the survival prognosis of the patient is poor, and if the expression level of the CX3CR1 gene of the patient is greater than the predetermined expression threshold, the survival prognosis of the patient is good.
申请公布号 US9110079(B2) 申请公布日期 2015.08.18
申请号 US201113242412 申请日期 2011.09.23
申请人 BIOMERIEUX;HOSPICES CIVILS DE LYON (HCL) 发明人 Cazalis Marie-Angélique;Pachot Alexandre;Tissot Sylvie;Monneret Guillaume
分类号 C12Q1/68;G01N33/68 主分类号 C12Q1/68
代理机构 Oliff PLC 代理人 Oliff PLC
主权项 1. An in vitro method of providing a survival prognosis for a patient having SIRS, the method comprising: measuring expression levels of a combination of target genes from biological material of a sample obtained from the patient using reagents specific for the respective target gene products that are selected from the group consisting of probes, primers, antibodies, and antibody fragments; comparing the expression levels to one or more predetermined thresholds indicative of a survival prognosis for the patient; and providing a survival prognosis for the patient so that care for the patient is able to be determined in accordance with the survival prognosis, wherein the combination of target genes includes at least one CX3CR1 gene and at least one other target gene selected from the group consisting of S100A8, S100A9, IL-10, TNFA, HLA-DR, CIITA, and IRAK3.
地址 Marcy L'Etoile FR